Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.

Structure Therapeutics Inc.’s shares rose after more data on the company’s experimental weight-loss pill showed it’s shaping up to rival new oral treatments from Novo Nordisk A/S and Eli Lilly & Co.

The database of 200 million protein-structure predictions now includes homodimers, adding new biological relevance.

For years, biomolecular condensates were thought to be simple, liquid-like droplets with little internal organization. New ...

The most common side effects of mRNA vaccines like the COVID-19 shot are well known: soreness, mild fever, and general ...

Obesity increases the body's need for insulin, forcing cells in the pancreas known as beta cells to ramp up insulin ...

Endocrine disruptor chemicals (EDCs) represent a critical area in environmental health, given their ubiquitous presence and profound ability to interfere ...

Researchers at The Hospital for Sick Children (SickKids) have uncovered how the bacteria that causes tuberculosis fuels itself during infection, providing new insights into one of the world's ...

Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which ...

From tiny cells to vast cities, life persists by keeping chaos under control. The same thermodynamic forces that cause coffee ...